Literature DB >> 7822800

Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence.

G G MacPherson1, C D Jenkins, M J Stein, C Edwards.   

Abstract

Dendritic cells (DC) acquire Ag in peripheral tissues and transport it to lymph nodes where they efficiently activate resting T cells. We have shown that i.v. endotoxin causes increased release of intestinal DC into lymph. In this paper we further characterize the release of DC and the properties of the released cells. A total of 50 micrograms of endotoxin injected i.v. causes an increase in DC output within 6 h that peaks between 12 and 24 h, with a maximum output of 8 to 15 times normal. At the same time lymphocyte output is markedly decreased. The increased output of DC is followed by a decrease to subnormal levels. The stimulated release of DC is almost totally blocked by a monoclonal anti-TNF-alpha Ab. A second injection of TNF-alpha does not result in further DC release. DC are not released from lymph nodes into efferent lymph by endotoxin. DC collected from lymph after endotoxin treatment show increased expression of the p55 IL-2 receptor and the OX48 Ag but otherwise resemble normal lymph DC. In functional assays they show no significant differences from normal in their ability to stimulate a MLR or to present Ags to sensitized T cells. Immunocytochemistry with the use of MRC OX62 suggests that the DC are released into lymph from the lamina propria of the small intestine. The stimulated release of DC mediated by TNF-alpha may be important in regulating Ag presentation in lymph nodes draining inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822800

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  In vivo maturation and migration of dendritic cells.

Authors:  L Flores-Romo
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

Review 2.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 3.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 4.  Tumour necrosis factor in mouse models of chronic intestinal inflammation.

Authors:  Christoph Mueller
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

Review 5.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

Review 6.  From optical bench to cageside: intravital microscopy on the long road to rational vaccine design.

Authors:  Heather D Hickman; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Production of interleukin (IL)-10 and IL-12 by murine colonic dendritic cells in response to microbial stimuli.

Authors:  R J Rigby; S C Knight; M A Kamm; A J Stagg
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 8.  The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria.

Authors:  A J Stagg; A L Hart; S C Knight; M A Kamm
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 9.  Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages.

Authors:  B Kelsall
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

10.  Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation.

Authors:  M Saurwein-Teissl; K Zisterer; T L Schmitt; R Glück; S Cryz; B Grubeck-Loebenstein
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.